Moreover, the application of AKT, mTOR and PI3K inhibitors to patients with HNCS has been achieved only up to phase II of clinical trials, and some studies have even investigated them in combination with cetuximab or cytostatic drugs for oral cancer therapy [12]. This evidence concerns the gene MTOR and lip and oral cavity carcinoma.